Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

PRECOS Launches PUMA at AACR 2013

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Company launches portfolio of techniques and models of acquired resistance to targeted agents and standards of care used in oncology.

Preclinical Oncology Services Limited (PRECOS) has launched PRECOS Unique Models of Acquired resistance (PUMA) at the AACR annual meeting (Washington DC, April 6th - 10th).

Derived from cell lines and proprietary PDX (Patient-Derived Xenograft) models, PUMA models provide a unique bespoke collection of clinically relevant and validated models of resistance, as well as the techniques and expertise to develop client specific models of acquired resistance to chemotherapeutics and targeted agents.

Such models are a major advancement for pharmaceutical and biotech companies running oncology R&D programmes and will enhance success rates during the critical phase of transitioning from pre-clinical to clinical evaluation of new drug candidates.

The first available examples of PUMA models are in specific lung cancer subsets where PRECOS has previously developed and characterized a focused panel of PDX lung cancer models derived directly from Caucasian patient tumour material - PRECOS’ unique model atlas LION (Lung In ONcology).

By repeatedly challenging relatively homogeneous cell line populations (CTX models) and heterogeneous tumours from PDX models across several passages, PRECOS is able to compare and contrast behaviour such as growth characteristics with gene expression and pathway analysis, response to chemotherapeutics and targeted agents.

It is also possible to assess the effect of varying treatment regimens and dosing strategies including drug holidays or combination therapies.

This allows panels of tumour subset specific models to be built which are able to mimic patients and their responses to treatment regimes in the clinic.

PRECOS is committed to further developing PUMA and is continuing to progress the techniques to provide customized services.

This will enable its clients to build models based on the characteristics of diverse cancer cell types which can offer insights for designing optimal treatment strategies around their pre-clinical candidates prior to product development and clinical trials.

“As oncology R&D progresses, there is an increasingly critical need for more clinically-relevant predictive pre-clinical models in order to overcome the high attrition rates of agents entering clinical trials,” said Dr Martin Page, Scientific Consultant, PRECOS.

Dr Page continued, “All new agents entering phase 1 clinical trials will be tested in cancer patients that have likely become resistant to a range of targeted and chemotherapeutic agents. PUMA is part of our PREdict platform, and offers PRECOS’ clients pre-clinical models that are authentic counterparts of the drug-resistant tumour subsets seen in the clinic, rather than drug-naive models. PRECOS’ latest portfolio offers specialist drug resistant pre-clinical models with responses of higher predictability with outcomes that can be seen during clinical testing.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Latest Advances in PDX Modelling for Oncology Drug Discovery
PRECOS' co-presentation with Crown Bioscience from Tumor Models Boston 2013 meeting available for download.
Friday, September 13, 2013
PRECOS Awarded HTA License and Expands PDX Drug Discovery Models
Company has been awarded license to store and research human tissue samples by the Human Tissue Authority.
Monday, August 27, 2012
PRECOS Appoints Dr Martin Page as Scientific Consultant
Appointment reinforces the ambition of PRECOS to contribute to the growing cancer therapy market.
Tuesday, February 21, 2012
PRECOS and Argenta Extend Collaboration to Offer World Class Integrated Oncology Drug Discovery Services
Five-year extension of the alliance allows both companies to offer unrivalled expertise in cancer research to their pharmaceutical clients.
Wednesday, March 23, 2011
PRECOS Doubles Capacity and Appoints New Senior Scientific Staff to Accommodate Significant Growth
The company has expanded to accommodate existing and anticipated growth in line with its leadership in oncology drug discovery.
Tuesday, February 15, 2011
Scientific News
Genes That Protect African Children From Developing Malaria Identified
Variations in DNA at a specific location on the genome that protect African children from developing severe malaria, in some cases nearly halving a child’s chance of developing the life-threatening disease, have been identified in the largest genetic association study of malaria to date.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
Dormant Viral Genes May Awaken to Cause ALS
NIH human and mouse study may open an unexplored path for finding treatments.
Scientists Create World’s Largest Catalog of Human Genomic Variation
An international team of scientists from the 1000 Genomes Project Consortium has created the world’s largest catalog of genomic differences among humans, providing researchers with powerful clues to help them establish why some people are susceptible to various diseases.
Five Genetic Regions Implicated In Cystic Fibrosis Severity
An international consortium of researchers conducted the largest-ever CF genome-wide analysis to find new therapeutic targets.
Greater Understanding Of Polycystic Ovary Syndrome
A new genetic study of over 200,000 women reveals the underlying mechanisms of polycystic ovary syndrome, as well as potential interventions.
New Autism Genes Are Revealed in Largest-Ever Study
Work draws more detailed picture of genetic risk, sheds light on sex differences in diagnosis.
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Genetic Adaptations to Diet and Climate
Researchers found genetic variations in the Inuit of Greenland that reflect adaptations to their specific diet and climate.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos